Company Performance Metrics
- Karl von Mangoldt: Managing Director and Founder
- Conrad Rasmus: Co-CEO & Co-Founder
ProtEmbo is designed to be a simple and reliable solution for one of the most feared complications during TAVR.
The advent of transcatheter treatments for valvular heart disease has been a major revolution in the care of patients with disabilities or intercurrent illnesses that precluded undergoing stressful open cardiac surgical procedures.
Nonetheless, in spite of ongoing improvements in TAVR procedures and outcomes, the occurrence of cerebrovascular events represents a significant morbidity of TAVR.
Protembis was founded based on the vision to reduce the risk of cerebrovascular events, thereby improving outcomes and making TAVR even safer – especially in light of TAVR shifting to younger and lower-risk patients. The ProtEmbo System is an adjunctive device used during TAVR and removed following completion of valve implantation. The ProtEmbo is an intra-aortic filter device that is designed to deflect embolic material arising during TAVR away from the cerebral circulation.
